Cargando…

Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials

BACKGROUND: This study compared response rates and outcomes of combined radiotherapy and immunotherapy (iRT) based on the type of checkpoint inhibitor (anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) vs antiprogrammed death-1 (PD1)) for metastatic non-small cell lung cancer (mNSCLC). METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Dawei, Menon, Hari, Verma, Vivek, Guo, Chunxiao, Ramapriyan, Rishab, Barsoumian, Hampartsoum, Younes, Ahmed, Hu, Yun, Wasley, Mark, Cortez, Maria Angelica, Welsh, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057428/ https://www.ncbi.nlm.nih.gov/pubmed/31996395 http://dx.doi.org/10.1136/jitc-2019-000492

Ejemplares similares

Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy
por: Cortez, Maria Angelica, et al.
Publicado: (2020)

Bone morphogenetic protein 7 promotes resistance to immunotherapy
por: Cortez, Maria Angelica, et al.
Publicado: (2020)

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2023)

High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model
por: Hu, Yun, et al.
Publicado: (2021)

Radiation and Anti-Cancer Vaccines: A Winning Combination
por: Cadena, Alexandra, et al.
Publicado: (2018)

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model
por: Hu, Yun, et al.
Publicado: (2022)

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2023)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity
por: Chen, Dawei, et al.
Publicado: (2020)

Radiation Therapy Modulates Tumor Physical Characteristics to Reduce Intratumoral Pressure and Enhance Intratumoral Drug Delivery and Retention
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
por: Menon, Hari, et al.
Publicado: (2019)

Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer
por: Hu, Yun, et al.
Publicado: (2022)

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
por: Menon, Hari, et al.
Publicado: (2019)

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
por: Barsoumian, Hampartsoum B, et al.
Publicado: (2020)

Anti-glucocorticoid-induced Tumor Necrosis Factor–Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects
por: Schoenhals, Jonathan E., et al.
Publicado: (2018)

Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer
por: He, Kewen, et al.
Publicado: (2021)

Pulsed radiotherapy to mitigate high tumor burden and generate immune memory
por: Sezen, Duygu, et al.
Publicado: (2022)

Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches
por: Klein, Katherine, et al.
Publicado: (2020)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
por: Seidel, Judith A., et al.
Publicado: (2018)

Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance
por: Ganjoo, Shonik, et al.
Publicado: (2022)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Correction: Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials
Publicado: (2020)

Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases
por: He, Kewen, et al.
Publicado: (2021)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
por: Sové, Richard J, et al.
Publicado: (2022)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody
por: Azuma, Takeshi, et al.
Publicado: (2021)

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy
por: Ganjoo, Shonik, et al.
Publicado: (2023)

Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma
por: Jaberg-Bentele, Nicoletta F., et al.
Publicado: (2017)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
por: Wagner, Nikolaus B, et al.
Publicado: (2018)

4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4(+)CD25(+)FoxP3(+) T Regulatory Cell Suppression
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2016)

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
por: Bowyer, S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_huohja8cnu3o27cu7th3afovpt